All News

11 August 2009

BioInvent Announces Approval to start Phase I Trial for BI-505 in Multiple MyelomaAntibodies

10 August 2009

MedImmune Advances Three Oncology Programs Into the ClinicAntibodies

9 August 2009

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal CancerAntibodies

7 August 2009

Antisoma announces discontinuation of development of AS1402Antibodies

5 August 2009

PharmaGap Releases Results of Initial Testing For Novel Cancer Drug Compound at the Ottawa Hospital Research InstituteAntibodies

5 August 2009

FDA: Cancer Warnings Required for TNF BlockersAntibodies

4 August 2009

Facet Biotech Announces Daclizumab Program in Multiple Sclerosis to AdvanceAntibodies

4 August 2009

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)Antibodies

3 August 2009

FDA Approves Avastin for the Most Common Type of Kidney CancerAntibodies

3 August 2009

Merck KGaA Presented New Data On the Combination of Erbitux with Standard First-Line Therapy in Patients with NSCLCAntibodies

31 July 2009

ImmunoGen Announces Encouraging New Clinical Data with the Company’s IMGN901 Compound in the Treatment of Small-Cell Lung CancerAntibodies

31 July 2009

Merck KGaA Has Requested Re-examination of the CHMP Opinion for Erbitux in Non-Small Cell Lung CancerAntibodies

31 July 2009

BioInvent signs Licensing Agreement with Mitsubishi Tanabe Pharma Corporation for the Discovery and Development of Therapeutic AntibodiesAntibodies

31 July 2009

Update on FDA Registration of Actemra®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody for Rheumatoid ArthritisAntibodies

30 July 2009

ArmaGen engineers IgG-decoy receptor fusion proteinAntibodies

30 July 2009

Second Phase III Study Showed Lucentis Improved Vision in Patients with Retinal Vein OcclusionAntibodies

30 July 2009

Merck Serono and MSM Protein Technologies Establish Drug Discovery Collaboration Targeted to Complex Cell Surface ReceptorsAntibodies

30 July 2009

Debiopharm and MSM Protein Technologies sign agreement for Research and Development of Debio 0929, a Novel Oncology BiologicAntibodies

30 July 2009

GLAXOSMITHKLINE AND GENMAB ANNOUNCE TOP-LINE RESULTS FOR OFATUMUMAB IN RHEUMATOID ARTHRITISAntibodies

29 July 2009

Regulatory update: mepolizumab for the treatment of hypereosinophilic syndrome (HES)Antibodies

29 July 2009

European commission approves broader label for Avastin allowing combination with docetaxel for the first-line treatment of advanced (metastatic) breast cancerAntibodies

29 July 2009

BTG plc: AstraZeneca to progress CytoFab™ into Phase IIb studyAntibodies

28 July 2009

Active Biotech’s Cancer Project ANYARA Featured in Journal of Clinical OncologyAntibodies

27 July 2009

Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)Antibodies

24 July 2009

Merck KGaA Considers Appealing CHMP Opinion on Erbitux ATreatment for Non-Small Cell Lung CancerAntibodies

24 July 2009

Ilaris® recommended for European approval as new biologic drug to treat a rare but serious group of auto-inflammatory diseasesAntibodies

24 July 2009

Seattle Genetics Initiates Brentuximab Vedotin (SGN-35) Retreatment Clinical TrialAntibodies

24 July 2009

Regeneron Receives European Medicines Agency Positive Opinion for Marketing Authorization of Rilonacept for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)Antibodies

24 July 2009

MabThera receives positive opinion in Europe for treating patients whose chronic lymphocytic leukaemia returnsAntibodies

24 July 2009

OMT Announces a Breakthrough in the Development of a Novel Human Antibody PlatformAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Ustekinumab (Stelara) Biosimilars Pipeline Review

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review

PSMA-Targeted Therapy Pipeline Review

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics